Clinical Medicine: Pathology
Synopsis: An open access, peer reviewed electronic journal that covers histopathology, haematology, biochemistry, virology, parasitology, infection control and medical microbiology.
Indexing: 5 major databases. Pubmed indexing for NIH-funded research.
Processing time: Decision in 2 weeks for 90% of papers.
Visibility: Most popular article read 800+ times.
About this journal
Aims and scope:
Clinical Medicine: Pathology is an international, open access, peer reviewed journal which considers manuscripts on histopathology, haematology, biochemistry, virology, parasitology, infection control and medical microbiology.
Editorial standards and procedures:
Submissions, excluding editorials, letters to the editor and dedications, will be peer reviewed by two reviewers. Reviewers are required to provide fair, balanced and constructive reports.
Under our Fairness in Peer Review Policy authors may appeal against reviewers' recommendations which are ill-founded, unobjective or unfair. Appeals are considered by the Editor in Chief or Associate Editor.
Papers are not sent to peer reviewers following submission of a revised manuscript. Editorial decisions on re-submitted papers are based on the author's response to the initial peer review report.
Indexing:
This journal is indexed by the following services:
- Google Scholar
- CAS
- DOAJ
- SCOPUS
- Embase
SPARC Europe Seal award winner:
This journal has been awarded a SPARC Europe Seal. The Seal is an initiative of SPARC Europe (Scholarly Publishing and Academic Resources Coalition) and the Directory of Open Access Journals (DOAJ) which is awarded to journals applying a Creative Commons CC-BY copyright license and that make journal metadata accessible to DOAJ.
Amongst other important services DOAJ makes metadata OAI-compliant. This in turn enhances the visibility of papers and allows OAI-harvesters to include the details of journal articles in their services. We encourage readers to make use of this valuable resource. The DOAJ search page is available here.
National Institutes of Health Public Access Policy compliant:
As of April 7 2008, the US NIH Public Access Policy requires that all peer reviewed articles resulting from research carried out with NIH funding be deposited in the Pubmed Central archive.
If you are an NIH employee or grantee Libertas Academica will ensure that you comply with the policy by depositing your paper at Pubmed Central on your behalf.
Call for papers:
The Editor in Chief welcomes submissions. Submissions of the following types are invited:
- Original research articles.
- Reviews: comprehensive, authoritative, descriptions of any subject within the journal's scope. They may cover basic science and clinical reviews, ethics, pro/con debates, and equipment reviews.
- Commentaries: focused and opinionated articles on any subject within the journal's scope. These articles are usually related to a contemporary issue.
- Hypotheses: articles that present an original hypothesis backed solely by previously published results rather than any new evidence. They should outline significant progress in thinking that would also be testable.
- Letters to the Editor: these can be either a re-analysis of a previously published article, or a response to such a re-analysis from the authors of the original publication.
- Methodology articles: these discuss a new experimental method, test or procedure. The article must describe a demonstrable advance on what is currently available. The method needs to have been well tested and ideally, but not necessarily, used in a way that proves its value.
- Short reports: brief reports of data from original research.
- Meeting reports: a report pertaining to activity at a meeting or conference Articles published in this journal are immediately available without delay upon publication and enjoy substantial visibility.
- Case reports: reports of clinical cases that can be educational, describe a diagnostic or therapeutic dilemma, suggest an association, or present an important adverse reaction. Case reports must meet appropriate ethical standards.
All submissions are subject to prompt, objective and fair peer review in compliance with our Fairness in Peer Review Policy. Copyright in published articles remains with the author(s). Authors are continually informed of the progress of their paper and our staff are friendly and responsive.
One author recently wrote: "I would like to say that this is the most author-friendly editing process I have experienced in over 150 publications. Thank you most sincerely."
Criteria for publication:
Publication is dependent on peer reviewers' judgement of papers. Reviewers are asked to provide thoughtful and unbiased feedback to authors to ensure that the conclusions of papers are valid and manuscripts achieve reasonable standards of scholarliness and intelligibility.
Previous work in the field must be acknowledged and papers should read without unreasonable difficulty. Papers should fit comfortably within the scope of the journal.
Reviewers are asked to act in a fair, objective and constructive manner which maintains quality standards and helps authors to communicate their research. They are instructed that in areas of genuinely novel research issues may be raised which cannot immediately be resolved and that absolutely rigorous validation of data may therefore not be possible.
More information on the role of peer reviewers is available on the information for reviewers page. Where authors consider that reviewers have made recommendations which are unreasonable, unobjective or ill-founded they may appeal them to the Editor in Chief or Associate Editor under our Fairness in Peer Review Policy.
Articles submitted to other journals:
We are willing to consider papers which have been peer reviewed by other journals but not accepted for publication.
Services for authors:
Prior to peer review of your paper we can:
- Have your paper's reference style revised to meet our requirements,
- Have your paper's English revised by specialist English-speaking technical editors.
After peer review of your paper we can:
- Have your paper revised in accordance with peer reviewer's recommendations and have a summary of responses to the reviewers created by our specialist external substantive editors,
- Provide bound reprints of your article in colour or black and white ,
- Provide online-early rapid publication if your paper prior to typesetting.
What other authors have said:
Libertas Academica actively requests, receives and acts upon feedback from authors, readers and editorial boards. Here's what some recent authors have said about us:
"Within a couple of days the reviewers had been procured and the manuscript was out."
"The communication between your staff and me has been terrific. Whenever progress is made with the manuscript, I receive notice. Quite honestly, I've never had such complete communication with a journal."
"LA is different, and hopefully represents a kind of scientific publication machinery that removes the hurdles from free flow of scientific thought."
Article processing fees:
All submissions to this journal are subject to an article processing fee if they are accepted for publication. Article processing fees are used to fund the processing of your paper and development of the journal. Article processing fees are the only compulsory charge you will face and do not vary according to word count, page count, colour figures or any other factor. There is no additional charge for the author(s) to make any use of their article and no charge to readers to access it.
Full fee waivers are available for authors working in undeveloped nations and partial discounts of 20-50% are available to authors in other nations. Authors must be able to verifiably demonstrate their suitability for a discount or waiver. Availability of waivers and discounts is subject to monthly availability and is given at the publisher's discretion. Waivers and discounts must be applied for prior to submission. Neither are available after submission.
Register as a peer reviewer:
Do you wish to register as a peer reviewer? Or are you already a registered peer reviewer but you need to update your contact details? To register or update your details visit the peer reviewer registration form.
Applicants must be able to demonstrate at least five years of continuous experience in the journal's subject area including at least two in the previous 24 months.
Journal newsletter sent to subscribers in week 15, 2009. Register to receive future newsletters.
New call for papers sent to newsletter subscribers in week 7 2009. Readers who wish to be elligible to receive CFPs should subscribe to the newsletter.
Peer reviewers are sought. Click here to apply or to update your details.
This journal has been accepted for indexing by Elsevier's highly regarded SCOPUS index
Combined Hepatocellular Cholangiocarcinomas; Analysis of a Large Database
Mitchell S. Wachtel1, Yan Zhang2, Tom Xu2, Maurizio Chiriva-Internati3 and Eldo E Frezza4
1Department of Pathology. 2Department of Family Medicine. 3Department of Microbiology and Immunology. 4Department of Surgery, Texas Tech University Health Sciences Center.
Abstract
Aim: Combined hepatocellular cholangiocarcinoma (combined tumor) has been described as either a variant of hepatoma or a variant of cholangiocarcinoma. Prior studies evaluated fewer than 50 patients with combined tumors, precluding multivariate analyses. Posited was the notion that analysis of a large database would yield more definite answers.
Methods: This study used SEER (Surveillance, Epidemiology, and End Results Program of the National Cancer Institute) to analyze 282 combined tumors, 2,035 intrahepatic cholangiocarcinomas, and 19,336 hepatomas between the years 1973–2003. Multinomial logit regression calculated point estimates and 95% confidence intervals (c.i.) for relative risk (rr). Cox regression calculated point estimates and 95% confidence intervals (c.i.) for hazard ratios (ĥ).
Results: Men less often had cholangiocarcinomas than they had combined tumors (rr = 0.63, c.i. = 0.49–0.81). Hepatomas less often than combined tumors presented with distant spread (rr = 0.56, c.i. = 0.43–0.72). Men (rr = 1.50, c.i. = 1.17–1.93) and patients with a known Asian or Pacific birthplace (rr = 2.36, c.i. = 1.56–3.56) more often had hepatomas than they had combined tumors. Among patients not known to have an Asian/Pacific birthplace, a diagnosis of cholangiocarcinoma (ĥ = 0.72, c.i. = 0.63–0.82) or hepatoma (ĥ = 0.75, c.i. = 0.66–0.86) provided a better prognosis than did a diagnosis of combined tumor.
Conclusion: Combined tumors differ from hepatomas and cholangiocarcinomas in terms of distribution and survival patterns in the population; they should be considered neither cholangiocarcinomas nor hepatomas.
Readers of this also read:
- Fast Genes and Slow Clades: Comparative Rates of Molecular Evolution in Mammals
- Long Term Results after 3 Courses of ABVD Plus Subtotal Nodal Radiotherapy in 188 Adult Patients with Stage Ι,ΙΙ and ΙΙΙA Hodgin Lymphoma
- Octreotide in Palliative Treatment of Unresectable Cholangiocarcinoma: Is it Effective for Disease Stabilization?
- Quantification of Drug-Induced mRNA in Human Whole Blood ex vivo
- Ontologies for Bioinformatics
- 03/Apr/2009
Pharmacotherapeutic Options for Visceral Leishmaniasis - Current Scenario
- 23/Jan/2009
Pneumococcal Induced T-activation with Resultant Thrombotic Microangiopathy. A case report and overview (Provisional PDF)
- 08/Jan/2009
Pathology-Dependent Histological Changes of the Left Stellate Ganglia: A Cadaveric Study
- 30/Oct/2008
The Pathogenesis of Autism
- 18/Sep/2008
Histopathologic Review of Previously Negative Prostatic Core Needle Biopsies Following a New Diagnosis of Adenocarcinoma of the Prostate by Core Needle Biopsies: Implications for Quality Assurance Programs
- 16/Sep/2008
Progesterone and Estrogen Receptors in Neurofibromas of Patients with NF1
- 15/Sep/2008
Commonality Between Diabetes and Alzheimer’s Disease and A New Strategy for the Therapy
- 28/Jul/2008
Mutation Detection in the Menkes Gene AT P 7A Using the Protein Truncation Test
- 19/Jun/2008
Histological Changes on Liver Glycogen Storage in Mice (Mus musculus) Caused by Unbalanced Diets
- 23/Apr/2008
Combined Hepatocellular Cholangiocarcinomas; Analysis of a Large Database
- 19/Mar/2008
P16/Ki-67 Immunostaining is Useful in Stratification of Atypical Metaplastic Epithelium of the Cervix
- 19/Mar/2008
Combination of Immunohistochemistry and Ploidy Analysis to Assist Histopathological Diagnosis of Molar Diseases
- 19/Mar/2008
Sclerosing ‘Mucinous’ Blue Nevus: A Clinical Simulator of Dermatofibroma
- 19/Mar/2008
Squamous Differentiation and Cytokeratin Expression in an Osteosarcoma: A Case Report and Review of the Literature
- 18/Mar/2008
Tumorigenic Effects of Tamoxifen on the Female Genital Tract
- 01/Mar/2008
P16 and Ki67 Immunostains Decrease Intra- and Interobserver Variability in the Diagnosis and Grading of Anal Intraepithelial Neoplasia (AIN)
- 09/Feb/2008
First-ever Ischemic Stroke after a Flight in a Patient with Prior Poliomyelitis
- 01/Feb/2008